Factory Mutual Insurance Co. Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Factory Mutual Insurance Co. purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 3,900 shares of the biopharmaceutical company’s stock, valued at approximately $2,778,000.

Several other institutional investors have also recently bought and sold shares of the stock. State Street Corp increased its stake in shares of Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after buying an additional 61,277 shares during the period. International Assets Investment Management LLC boosted its holdings in Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Regeneron Pharmaceuticals by 1.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock valued at $707,759,000 after acquiring an additional 11,499 shares during the last quarter. Swiss National Bank increased its position in Regeneron Pharmaceuticals by 0.6% in the third quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock worth $338,079,000 after purchasing an additional 2,000 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. raised its holdings in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 301,508 shares of the biopharmaceutical company’s stock worth $316,957,000 after purchasing an additional 3,866 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on REGN shares. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Piper Sandler lowered their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a report on Monday, January 27th. Oppenheimer cut their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Royal Bank of Canada decreased their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Finally, BMO Capital Markets dropped their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,004.57.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $672.98 on Friday. The stock has a 50-day moving average price of $722.11 and a two-hundred day moving average price of $926.91. Regeneron Pharmaceuticals, Inc. has a 1 year low of $666.25 and a 1 year high of $1,211.20. The stock has a market cap of $73.95 billion, a PE ratio of 16.65, a price-to-earnings-growth ratio of 1.62 and a beta of 0.10. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.